Fidelity Investments’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $5.8B | Buy |
29,601,724
+18,677,296
| +171% | +$3.6B | 0.31% | 43 |
|
|
2025
Q4 | $2.01B | Buy |
10,924,428
+81,268
| +0.7% | +$14.3M | 0.1% | 152 |
|
|
2025
Q3 | $1.66B | Buy |
10,843,160
+172,301
| +2% | +$26.1M | 0.09% | 181 |
|
|
2025
Q2 | $1.49B | Sell |
10,670,859
-875,377
| -8% | -$123M | 0.08% | 190 |
|
|
2025
Q1 | $1.7B | Buy |
11,546,236
+390,477
| +4% | +$56.5M | 0.11% | 157 |
|
|
2024
Q4 | $1.46B | Sell |
11,155,759
-402,965
| -3% | -$56.4M | 0.09% | 178 |
|
|
2024
Q3 | $1.8B | Buy |
11,558,724
+129,239
| +1% | +$20.9M | 0.11% | 151 |
|
|
2024
Q2 | $1.78B | Buy |
11,429,485
+1,073,654
| +10% | +$162M | 0.11% | 133 |
|
|
2024
Q1 | $1.4B | Sell |
10,355,831
-305,169
| -3% | -$40.4M | 0.09% | 181 |
|
|
2023
Q4 | $1.44B | Buy |
10,661,000
+191,452
| +2% | +$24.9M | 0.11% | 158 |
|
|
2023
Q3 | $1.42B | Sell |
10,469,548
-940,601
| -8% | -$128M | 0.12% | 142 |
|
|
2023
Q2 | $1.63B | Buy |
11,410,149
+34,986
| +0.3% | +$5.15M | 0.14% | 128 |
|
|
2023
Q1 | $1.58B | Sell |
11,375,163
-227,849
| -2% | -$30.7M | 0.14% | 122 |
|
|
2022
Q4 | $1.57B | Sell |
11,603,012
-2,232,749
| -16% | -$280M | 0.16% | 117 |
|
|
2022
Q3 | $1.52B | Buy |
13,835,761
+1,070,383
| +8% | +$136M | 0.16% | 112 |
|
|
2022
Q2 | $1.69B | Buy |
12,765,378
+4,159,903
| +48% | +$546M | 0.17% | 100 |
|
|
2022
Q1 | $1.14B | Buy |
8,605,475
+1,240,563
| +17% | +$149M | 0.09% | 193 |
|
|
2021
Q4 | $858M | Sell |
7,364,912
-787,246
| -10% | -$92.6M | 0.06% | 293 |
|
|
2021
Q3 | $979M | Buy |
8,152,158
+3,895,157
| +92% | +$453M | 0.08% | 230 |
|
|
2021
Q2 | $510M | Sell |
4,257,001
-1,796,897
| -30% | -$197M | 0.04% | 422 |
|
|
2021
Q1 | $602M | Sell |
6,053,898
-6,647,126
| -52% | -$668M | 0.05% | 371 |
|
|
2020
Q4 | $1.27B | Sell |
12,701,024
-9,474,118
| -43% | -$1B | 0.11% | 163 |
|
|
2020
Q3 | $2.43B | Sell |
22,175,142
-1,678,128
| -7% | -$187M | 0.25% | 64 |
|
|
2020
Q2 | $2.52B | Sell |
23,853,270
-261,126
| -1% | -$27M | 0.28% | 53 |
|
|
2020
Q1 | $2.15B | Sell |
24,114,396
-2,424,976
| -9% | -$228M | 0.3% | 62 |
|
|
2019
Q4 | $2.65B | Buy |
26,539,372
+2,461,563
| +10% | +$232M | 0.29% | 59 |
|
|
2019
Q3 | $2.15B | Buy |
24,077,809
+1,716,888
| +8% | +$149M | 0.26% | 70 |
|
|
2019
Q2 | $1.85B | Sell |
22,360,921
-6,055,441
| -21% | -$475M | 0.22% | 87 |
|
|
2019
Q1 | $2.3B | Buy |
28,416,362
+229,376
| +0.8% | +$18.1M | 0.28% | 63 |
|
|
2018
Q4 | $2.14B | Buy |
28,186,986
+10,524,091
| +60% | +$822M | 0.29% | 61 |
|
|
2018
Q3 | $1.4B | Buy |
17,662,895
+7,541,304
| +75% | +$570M | 0.16% | 121 |
|
|
2018
Q2 | $711M | Buy |
10,121,591
+2,636,295
| +35% | +$190M | 0.08% | 230 |
|
|
2018
Q1 | $524M | Buy |
7,485,296
+1,140,876
| +18% | +$79M | 0.06% | 328 |
|
|
2017
Q4 | $440M | Buy |
6,344,420
+2,170,891
| +52% | +$146M | 0.05% | 390 |
|
|
2017
Q3 | $283M | Buy |
4,173,529
+2,202,017
| +112% | +$139M | 0.03% | 544 |
|
|
2017
Q2 | $134M | Sell |
1,971,512
-26,156
| -1% | -$1.71M | 0.02% | 841 |
|
|
2017
Q1 | $124M | Sell |
1,997,668
-730,289
| -27% | -$42.5M | 0.02% | 895 |
|
|
2016
Q4 | $149M | Sell |
2,727,957
-836,296
| -23% | -$47.5M | 0.02% | 811 |
|
|
2016
Q3 | $234M | Buy |
3,564,253
+2,753,443
| +340% | +$180M | 0.03% | 596 |
|
|
2016
Q2 | $49M | Buy |
810,810
+195,407
| +32% | +$11.3M | 0.01% | 1279 |
|
|
2016
Q1 | $34.7M | Sell |
615,403
-527,642
| -46% | -$31.7M | ﹤0.01% | 1407 |
|
|
2015
Q4 | $77.6M | Buy |
1,143,045
+46,633
| +4% | +$3.06M | 0.01% | 1072 |
|
|
2015
Q3 | $69.8M | Sell |
1,096,412
-161,628
| -13% | -$10.6M | 0.01% | 1105 |
|
|
2015
Q2 | $80.2M | Sell |
1,258,040
-313,984
| -20% | -$21.5M | 0.01% | 1134 |
|
|
2015
Q1 | $108M | Sell |
1,572,024
-686,464
| -30% | -$47.7M | 0.01% | 994 |
|
|
2014
Q4 | $159M | Sell |
2,258,488
-472,588
| -17% | -$33.8M | 0.02% | 783 |
|
|
2014
Q3 | $195M | Sell |
2,731,076
-1,685,212
| -38% | -$123M | 0.03% | 670 |
|
|
2014
Q2 | $328M | Sell |
4,416,288
-2,900,568
| -40% | -$210M | 0.04% | 455 |
|
|
2014
Q1 | $475M | Sell |
7,316,856
-1,377,193
| -16% | -$88.9M | 0.07% | 323 |
|
|
2013
Q4 | $516M | Buy |
8,694,049
+1,826,986
| +27% | +$99.2M | 0.07% | 293 |
|
|
2013
Q3 | $357M | Buy |
6,867,063
+746,811
| +12% | +$37.5M | 0.05% | 395 |
|
|
2013
Q2 | $289M | Buy |
+6,120,252
| New | +$312M | 0.05% | 434 |
|
Other funds holding AZN
IA
VCM
VAM
Fidelity Investments's AZN Position: Q1 2026 in Review
Fidelity Investments increased its AstraZeneca (AZN) stake by 171% in Q1 2026, buying an estimated $3.6B and bringing the position to 29,601,724 shares worth $5.8B. The position accounts for 0.31% of the portfolio, ranked #43.
Fidelity Investments first reported a position in AZN in Q2 2013 and has held it in 52 quarters since. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.
- Fidelity Investments held 29,601,724 shares of AstraZeneca worth $5.8B as of Q1 2026.
- Fidelity Investments bought 18,677,296 AstraZeneca shares in Q1 2026, an estimated $3.6B.
- AstraZeneca made up 0.31% of Fidelity Investments's portfolio in Q1 2026, its #43 holding.
- Fidelity Investments first reported a position in AstraZeneca in Q2 2013 and has held it in 52 quarters since.
- 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.
Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.